About the Event
Imagine treating cancer tumors with a single injection without affecting other organs in the body!
Invectys is a clinical stage cancer immunotherapy company developing breakthrough treatments based on a novel precision target, the Human Leukocyte Antigen-G (HLA-G). More than 70 percent of human cancers express HLA-G thus by targeting the those expressors, therapies go directly to the tumor minimizing damage to other organs. In animal models, T-Cell therapy targeting HLA-G cleared the lung of cancer metastases just 20 days after treatment.
Invectys will be moving into Phase 1 Clinical Trials this year, with the goal of completing Phase 2a on their first platform in 2024.
Join our webinar with Invectys President and CEO, Praveen Tyle, to learn more about the company’s three platforms and the technology that has the potential to cure metastatic cancers.